The chemical industry is seeing increasing costs for building petrochemical plants, including ethane crackers. Still, the U.S. enjoys "pretty staggering" cost advantages, said Anton Ticktin of investment bank Valence Group.
Carlyle Group's investment in Sunoco's Philadelphia refinery, which was slated to close, required coordination with officials from the company, multiple levels of government and a union, this analysis details. Carlyle is looking to use the advantages of natural gas and rail to make the refinery venture a success.
Mitsubishi Chemical will invest as much as $710 million for an acrylic resin-processing facility in Texas, according to a Japanese newspaper. A U.S. facility would offer cost savings compared with Japan-based production, the newspaper said.
Japanese researchers have produced inexpensive compounds based on carbazolyl dicyanobenzene that show promise for use in organic light-emitting diodes. Chemists designed the metal-free compounds that efficiently emit a light in a broad spectrum and could lead to displays that are lighter, thinner and flexible enough to be rolled up or used in clothing.
Investments in whole genome sequencing and analysis are starting to pay off, with new drugs, diagnostics and disease management strategies, Luke Timmerman writes. Two companies, Adaptive Biotechnologies and Sequenta, are pioneering new approaches to disease diagnosis and management through sequencing that would have been cost-prohibitive several years ago. Studies are under way to determine whether genomics technologies will lower health care costs and improve outcomes, but the personalized medicine payoff is imminent, Timmerman writes.